Carol McClure
Carol McClure has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Eric D. Anderson
Box 28, Group 30, RR2, Ste Anne, Manitoba, R5H 1R2, Canada
2 shared publications - Sharon C. Clouthier
Fisheries and Oceans Canada, Freshwater Institute, 501 University Crescent, Winnipeg, Manitoba, R3T 2N6, Canada
2 shared publications - Tamara Schroeder
Fisheries and Oceans Canada, Freshwater Institute, 501 University Crescent, Winnipeg, Manitoba, R3T 2N6, Canada
2 shared publications - Crystal Collette-Belliveau
Fisheries and Oceans Canada, Gulf Fisheries Center, 343 University Avenue, Moncton, New Brunswick, E1C 9B6, Canada
1 shared publication Garth Traxler
Department of Fisheries and Oceans, Pacific Biological Station, Nanaimo, British Columbia, V9T 6N7, Canada
1 shared publicationGrace Karreman
Pacific Marine Veterinary Services, 3000 Andre Road, Nanaimo, British Columbia, V9R 6×2, Canada
1 shared publication
Latest Publications
- Open Access
- 1 May 2021
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 190, 105338
Bayesian latent class model estimates of diagnostic accuracy for three test methods designed to detect spring viremia of carp virus
- 1 May 2021
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 190, 105338
Open AccessBayesian latent class model estimates of diagnostic accuracy for three test methods designed to detect spring viremia of carp virus
- Open Access
- 1 March 2021
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 188, 105288
Measures of diagnostic precision (repeatability and reproducibility) for three test methods designed to detect spring viremia of carp virus
- 1 March 2021
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 188, 105288
Open AccessMeasures of diagnostic precision (repeatability and reproducibility) for three test methods designed to detect spring viremia of carp virus
- 1 March 2008
- Published by Oxford University Press (OUP) in Journal of Aquatic Animal Health
- Vol. 20 (1) , 12-18
Evaluation of a Reverse Transcriptase Polymerase Chain Reaction Test and Virus Isolation on Field Samples Collected for the Diagnosis of Infectious Hematopoietic Necrosis Virus in Cultured Atlantic Salmon in British Columbia
Infectious hematopoietic necrosis virus (IHNV) has been found to cause disease in cultured salmon of the Pacific Northwest region of North America. Diagnosis of IHNV by virus isolation (VI) can take over 2 weeks. Recently, a rapid reverse transcriptase (RT) polymerase chain reaction (PCR) test on fish tissues has been used for diagnosis. Test performances of the VI and RT PCR assays were compared using samples collected in the field. The effect of different storage conditions (tissue frozen with or without RNAlater (Ambion, Inc., Austin, Texas) versus fresh tissue) on the diagnostic tests was also evaluated. Based on the limited number of samples tested, the operating characteristics of RT PCR were very similar to those of VI; therefore, this method is likely suitable for testing field samples for IHNV. The ability of the tests to identify a positive fish ranged from 74% to 89%. Freezing samples at −80°C before testing did not negatively affect the performance of RT PCR or VI. However, due to reduced test performance, RNAlater frozen storage is not recommended without further investigation.
- 1 March 2008
- Published by Oxford University Press (OUP) in Journal of Aquatic Animal Health
- Vol. 20 (1) , 12-18
Evaluation of a Reverse Transcriptase Polymerase Chain Reaction Test and Virus Isolation on Field Samples Collected for the Diagnosis of Infectious Hematopoietic Necrosis Virus in Cultured Atlantic Salmon in British Columbia
Infectious hematopoietic necrosis virus (IHNV) has been found to cause disease in cultured salmon of the Pacific Northwest region of North America. Diagnosis of IHNV by virus isolation (VI) can take over 2 weeks. Recently, a rapid reverse transcriptase (RT) polymerase chain reaction (PCR) test on fish tissues has been used for diagnosis. Test performances of the VI and RT PCR assays were compared using samples collected in the field. The effect of different storage conditions (tissue frozen with or without RNAlater (Ambion, Inc., Austin, Texas) versus fresh tissue) on the diagnostic tests was also evaluated. Based on the limited number of samples tested, the operating characteristics of RT PCR were very similar to those of VI; therefore, this method is likely suitable for testing field samples for IHNV. The ability of the tests to identify a positive fish ranged from 74% to 89%. Freezing samples at −80°C before testing did not negatively affect the performance of RT PCR or VI. However, due to reduced test performance, RNAlater frozen storage is not recommended without further investigation.
- Open Access
- 1 January 2006
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 17 (1) , 19-26
Pneumococcal Conjugate Vaccination in Canadian Infants and Children Younger than Five Years of Age: Recommendations and Expected Benefits
INTRODUCTION: Streptococcus pneumoniae infection may result in invasive pneumococcal disease (IPD), such as bacteremia, meningitis and bacteremic pneumonia, or in non‐IPD, such as pneumonia, sinusitis and otitis media. In June 2001, a heptavalent pneumococcal conjugate vaccine (PCV7) (Prevnar, Wyeth Pharmaceuticals, Canada) was approved for use in children in Canada. The objective of the present paper is to review S pneumoniae‐induced disease incidence and vaccine recommendations in Canadian infants and children younger than five years of age. Particular attention is given to the expected benefits of vaccination in Canada based on postmarketing data and economic modelling.METHODS: Searches were performed on PubMed and Web of Science databases and specific Canadian journals using the key words ′pneumococc*′, ′vaccine′, ′conjugate′, ′infant′ and ′Canadian′.RESULTS AND DISCUSSION: PCV7 appears to be safe and effective against IPD and non‐IPD in children younger than five years of age and, more importantly, in children younger than two years of age (who are at highest risk for IPD). An examination of postmarketing data showed a reduction in incidence of pneumococcal disease in age groups that were vaccinated and in older age groups, indicating the likelihood of herd protection. Concurrently, there was a reduction in the occurrence of antimicrobial‐resistant isolates.CONCLUSIONS: The results from the present review suggest that PCV7 is currently benefiting Canadian children and society by lowering S pneumoniae‐associated disease. Additional gains from herd protection and further reductions in antimicrobial resistance will be achieved as more Canadian children younger than five years of age are routinely vaccinated with PCV7.
- 1 January 2006
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 17 (1) , 19-26
Open AccessPneumococcal Conjugate Vaccination in Canadian Infants and Children Younger than Five Years of Age: Recommendations and Expected Benefits
INTRODUCTION: Streptococcus pneumoniae infection may result in invasive pneumococcal disease (IPD), such as bacteremia, meningitis and bacteremic pneumonia, or in non‐IPD, such as pneumonia, sinusitis and otitis media. In June 2001, a heptavalent pneumococcal conjugate vaccine (PCV7) (Prevnar, Wyeth Pharmaceuticals, Canada) was approved for use in children in Canada. The objective of the present paper is to review S pneumoniae‐induced disease incidence and vaccine recommendations in Canadian infants and children younger than five years of age. Particular attention is given to the expected benefits of vaccination in Canada based on postmarketing data and economic modelling.METHODS: Searches were performed on PubMed and Web of Science databases and specific Canadian journals using the key words ′pneumococc*′, ′vaccine′, ′conjugate′, ′infant′ and ′Canadian′.RESULTS AND DISCUSSION: PCV7 appears to be safe and effective against IPD and non‐IPD in children younger than five years of age and, more importantly, in children younger than two years of age (who are at highest risk for IPD). An examination of postmarketing data showed a reduction in incidence of pneumococcal disease in age groups that were vaccinated and in older age groups, indicating the likelihood of herd protection. Concurrently, there was a reduction in the occurrence of antimicrobial‐resistant isolates.CONCLUSIONS: The results from the present review suggest that PCV7 is currently benefiting Canadian children and society by lowering S pneumoniae‐associated disease. Additional gains from herd protection and further reductions in antimicrobial resistance will be achieved as more Canadian children younger than five years of age are routinely vaccinated with PCV7.